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Abstract 
Dietary nitrate (found in green leafy vegetables such as rocket and in beetroot) is now 
recognised to be an important source of nitric oxide, via the nitrate-nitrite-NO pathway. 
Dietary nitrate confers several cardiovascular beneficial effects on blood pressure, platelets, 
endothelial function, mitochondrial efficiency and exercise. Whilst this pathway may now 
seem obvious, its realisation followed a rather tortuous course over two decades. Early steps 
included the discovery that nitrite was a source of NO in the ischaemic heart, but this 
appeared to have deleterious effects. In addition, nitrate-derived nitrite provided a gastric 
source of NO. However, residual nitrite was not thought to be absorbed systemically. Nitrite 
was also considered to be physiologically inert, but potentially carcinogenic, through N-
nitrosamine formation. In Part I we describe key twists and turns in the elucidation of the 
pathway and the underlying mechanisms.  This provides the critical foundation for the more 
recent developments in the nitrate-nitrite-NO pathway which are covered in Part II. 
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Introduction 
Whilst the nitrate-nitrite-NO pathway has now largely been accepted as an alternative source 
of nitric oxide with an expanding range of beneficial effects, the characterisation of the 
kinetic processes leading to the realisation of the pathway was not straightforward. In Part I 
we describe key twists and turns in the establishment of the pathway over the last 2 
decades.  
 
Background to nitrate/nitrite’s established properties?  
Inorganic nitrate (NO3
-) has a long history as an explosive agent, being a major component 
of gun powder, as described in a Chinese manual of war from 1044 AD [1].  It was also used 
in Chinese medicine for angina as described in an 8th century Chinese manuscript from the 
Dunhuang collection [1].  Inorganic nitrate was largely superseded when the organic (i.e., 
carbon-containing) nitrate compound, nitroglycerin, synthesised by Sobrero in 1812 [2], was 
stabilised and developed as dynamite by Alfred Nobel. Nitroglycerin was subsequently used 
medicinally (and renamed glyceryl trinitrate (GTN) to distinguish it from the explosive) to 
treat angina (including by Nobel). Although prior to the use of GTN, isoamyl nitrite was used, 
it was subsequently abandoned in favour of organic nitrates due to its shorter half-life, and 
along with isopropyl and isobutyl nitrite became drugs of abuse (poppers). As 
nitrovasodilators, organic nitrates and nitrites were considered to relax vascular smooth 
muscle via activation of soluble guanylate cyclase (sGC) resulting in elevation of cGMP 
either directly or through metabolism to NO, thus increasing coronary blood flow for example 
[3]. Although potassium nitrate was used as a weak diuretic in the early 20th Century [4] 
inorganic nitrite (NO2
-) and nitrate have had minimal role therapeutically, and more recently 
as ‘stable end products of NO metabolism’ it was not thought that they could be metabolised 
back to NO in biological systems. The only current medicinal indication for sodium nitrite is 
as a treatment for cyanide poisoning. 
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Whilst they have had minimal therapeutic use, the inorganic nitrate and nitrite anions are 
common constituents of our diet. Relatively small amounts of nitrite occur naturally in food; 
however, nitrite (E249, E250) is commonly added in the curing process to preserve meats. 
By contrast, nitrate is found in large quantities in green leafy vegetables e.g. spinach and 
lettuce, as well as beetroot (red beet) and is also an EU-approved food additive (E251, 
E252). Despite these abundant sources, typically-ingested quantities of nitrate do not 
account for the majority of nitrate exposure. For example, Green et al. (1981) found that 
urinary nitrate excretion over 24 hours exceeded the amount of nitrate ingested (whether 
small or large quantities) by four-fold [5].  This suggested substantial endogenous nitrate 
production. Following the discovery of endothelium-derived relaxing factor (EDRF) as nitric 
oxide (NO), the pathway was elucidated by the same group, whereby Leaf et al. (1989) 
showed that consumption of [15N] L-arginine led to 15NO3
- excretion in the urine, confirming 
L-arginine as the ultimate precursor for nitrate [6]. Thus L-arginine is the substrate for the 
NO synthases (NOS), resulting in NO production. Nitric oxide has multiple biological 
functions, including being one of the most potent vasodilators in man [7]. In addition to 
nitrate, spinach also contains high concentrations of L-arginine. However, L-arginine has 
rather poor oral bioavailability compared to L-citrulline, found in foods such as watermelon 
[8] and which is metabolised to L-arginine [9].  
 
As a reactive free radical, NO possesses a short half-life of milliseconds in the circulation, 
being oxidised to nitrite and nitrate by oxygen and oxy-haemoglobin (oxyHb) [10].  In 
contrast to NO, nitrite and nitrate were thought to lack any useful physiological effect, being 
merely considered as “inert oxidative end products of endogenous NO metabolism” [10, 11], 
and as such were useful for measuring the activity of vasoactive NO [10].  Therefore, the 
metabolic sequence of L-arginine–NO–NO2
-–NO3
- became firmly established (though never 
described as a distinct “L-arginine-nitric oxide-nitrite-nitrate pathway”) with the focus on NO’s 
activity.  
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Besides being considered to lack any useful physiological effect, nitrite had been implicated 
as a potential carcinogen through the formation of N-nitrosamines [12], with concerns that it 
may lead to the development of oesophago-gastric cancers [13]. Coupled with reports of 
infantile methaemoglobinaemia, this led to the imposition of the maximum concentration of 
nitrate in tap water by authorities [14].   
 
However, such concerns over nitrate are inconsistent with ‘healthy’ diets such as vegetarian 
diets and the Mediterranean diet, since these diets typically consist of fresh fruit and 
vegetables, particularly green leafy varieties, which are high in dietary nitrate, along with 
high amounts of unsaturated fats and low amounts of red meat. Vegetarian diets have been 
shown to reduce blood pressure when compared to omnivorous diets [15, 16]. The DASH 
(Dietary Approaches to Stop Hypertension) study showed that a ‘combination-diet’ high in 
fruit, vegetables and low fat dairy produce, and low in saturated fat, reduced blood pressure 
compared to a control diet (low in fruit, vegetables and dairy products, but high in saturated 
fat) [17]. Whilst the mechanisms for this may be multifactorial, the daily nitrate content has 
been estimated to be ~1200 mg (i.e., ~19 mmol) in the DASH diet [18].  Epidemiological 
evidence from the studies by Joshipura et al. suggested the importance of green leafy 
vegetables (high in dietary nitrate) in the protection against coronary heart disease and 
ischaemic stroke [19, 20].  
 
Recent prospective interventional trial evidence supporting the Mediterranean diet is 
provided by a large multicentre parallel randomised controlled trial performed by Estruch et 
al., (2013). This was conducted in participants with high cardiovascular risk (without 
established cardiovascular disease) who were allocated to one of three groups: two groups 
that followed a Mediterranean diet with an additional supplement (either a litre of olive oil per 
week or a selection of mixed nuts), and one control diet (advice to reduce dietary fat) [21]. 
Over a median follow up of 4.8 years, the study demonstrated a ~30% reduction in major 
cardiovascular events (myocardial infarction, stroke, death from cardiovascular causes) with 
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the Mediterranean diets compared with the control diet. The potential for dietary nitrate to be 
an important factor in such healthy diets will be addressed by considering the following 
questions. 
 
 
1. Is nitrite a source of NO? 
It had long been acknowledged that nitrite is reduced to NO under acidic conditions. 
However, the potential physiological relevance had not been appreciated.   NO production 
from nitrite was originally demonstrated in tissues under hypoxia/ischaemia, conditions 
associated with an acidic reducing environment. Zweier et al. measured NO production from 
nitrite using Electron Paramagnetic Resonance (EPR) spectroscopy in isolated rat hearts 
[22]. Under normal perfusion (control), NO production was absent. When subjected to 30 
minutes of ischaemia, a strong signal was detected on EPR, indicating NO production. The 
intensity of this signal was 100-fold higher in the presence of added nitrite. Using ¹⁵NO₂⁻ and 
observing the generation of ¹⁵NO, it was confirmed that the NO was derived from nitrite. 
These effects were seen with a background of NOS inhibition i.e. this was a NOS-
independent mechanism of NO generation. The quantity of NO produced was inversely 
associated with the pH of the heart: the lower the pH, the greater the NO production. From 
this, the authors concluded that NO is produced from nitrite under the reducing environment 
found in hypoxic/ischaemic/acidic conditions, in contrast to the conventional oxygen-
dependent production of NO from NOS, which is inhibited by hypoxia and ischaemia [23].  
 
2. What effect does nitrite have in IRI?  
Twenty years ago, nitrite appeared to be predominantly harmful. Zweier et al. (1995) found 
that increasing NO production by adding 10 µM nitrite (enzyme independent) increased post-
ischaemic myocardial injury in a model of ischaemia-reperfusion injury (IRI) in the isolated 
perfused Langendorff rat heart [22]. However, the percentage recovery of the rate pressure 
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product was <10% in control. Administration of the NOS inhibitor, N-nitro L-arginine methyl 
ester (L-NAME), decreased NO production by approximately 65% and led to a two-fold 
increase in recovery of contractility, suggesting that NO produced from nitrite could be 
damaging to myocardial tissue.  Understandably, as a result of these findings of a 
deleterious effect of nitrite/NO in IRI, along with the notion that nitrite produced carcinogenic 
nitrosamines, and that NO was a pollutant in the atmosphere, interest in nitrite waned. 
   
Almost a decade later, Webb et al. found that in a similar IRI model, nitrite (10 and 100 µM) 
substantially reduced infarct size and preserved left ventricular pressure following 
reperfusion [24]. This protective effect was lost in the presence of the NO scavenger 2-(4- 
carboxyphenyl)-4,4,5,5-tetramethylimidazole-1-oxyl 3-oxide (carboxy- 
PTIO), suggesting that nitrite-derived NO was beneficial. These findings were consistent with 
an emerging protective rather than damaging function of NO from NOS, as reviwed by Bolli 
et al., [25]. For example, infarct size had been found to larger in hearts of endothelial NOS 
(eNOS) knockout mice compared to wild type [26].  
 
The majority of studies subsequently performed with nitrite supported a protective effect in 
IRI (Table 1). For example, Duranski et al. demonstrated protective effects of nitrite in vivo 
during IRI of both the liver and the heart in rats [27]. Nitrite limited the rise in liver enzymes 
during hepatocellular injury, and diminished hepatocellular necrosis, whilst intraventricular 
nitrite (48 nmol) prior to reperfusion of the ischaemic heart reduced infarct size by 67%. 
Administration of nitrite at the time of reperfusion was also effective in limiting infarct size in 
the brain in a rat model of stroke [28]. Table 1 summarises some of the early studies 1995-
2008 which helped establish the role of nitrite IRI, up to the study in dogs by Gonzalez et al. 
[29].  
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Within a decade, the original discovery of cardio-protection with nitrite in IRI had been 
translated into two clinical trials in patients with acute ST-elevation myocardial infarction 
(STEMI). In a double-blind placebo- controlled randomised parallel-group trial, Siddiqi et al. 
(2014) investigated the effects of intravenous sodium nitrite immediately prior to reperfusion 
in 229 patients with acute STEMI. Myocardial infarct size (the primary endpoint, measured in 
terms of the extent of gadolinium enhancement by cardiac MRI 6-8 days post-infarct) did not 
differ significantly between the groups [35]. It is possible that the dose given (70 µmol) was 
not sufficient to achieve a significant effect. Jones et al. used the intracoronary, rather than 
the intravenous route, delivering a high local dose of nitrite (1.8 µmol) prior to balloon 
dilatation during percutaneous coronary intervention (PCI) in 80 patients with acute STEMI 
[36]. There was no overall difference in the primary outcome - infarct size (versus placebo), 
measured by the area under the curve of creatine kinase (AUC CK) profile over 48 hours. 
However, there was an overall improvement (P=0.05) in myocardial salvage index 
(measured in a subgroup of 68 patients with cardiac MRI) and reduction in major adverse 
cardiac event at 1 year. In a sub-group analysis (n=66) in patients who had Thrombolysis In 
Myocardial Infarction (TIMI) flow grade score ≤1, there was a significant 19% reduction in 
AUC CK profile and cardiac MRI-determined infarct size. These findings are entirely 
compatible with the mechanism of action of nitrite - which requires an ischaemic 
environment, rather than one in which reperfusion has already partially occurred, and this 
deserves to be followed up in further trials.   
 
3. Does nitrite dilate blood vessels?  
Furchgott had shown in 1952 that high concentrations of sodium nitrite (100 and 1000 μM) 
relaxed strips of rabbit  thoracic aorta [37]. However, these concentrations are >100-fold 
greater than physiological concentrations of nitrite in the circulation, which are usually ~0.1-
0.4 μM.  Cicinelli et al. (1999) postulated the existence of an arterial-to-venous (AV) gradient 
of NO, after measuring higher quantities of NO metabolites nitrite and nitrate, in arterial 
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samples than paired venous samples in healthy volunteers [38]. A year later, Gladwin et al. 
clearly demonstrated the presence of an AV nitrite gradient [39], which further suggested 
that nitrite is reduced to NO across the vascular bed, with a greater difference shown during 
handgrip exercise associated with oxygen extraction by the muscles from the vessels, and 
consistent with enhanced nitrite reduction to NO under condition s of lower oxygen tension.    
However, whether nitrite could actually dilate vessels was not clear. In 2001, Lauer et al. 
showed that whilst regional nitrite concentration rose acutely following endothelial NOS 
stimulation with acetylcholine, reflecting changes in NO generation, the intrabrachial infusion 
of nitrite failed to produce any vasodilation [40]. In the same year, Modin et al. analysed the 
effects of nitrite in rat aortic rings at concentrations which resembled physiological states and 
its effect on aortic contractility upon reaching a “physiologically acidic milieu” (pH 6.6). The 
EC50 for nitrite-induced relaxation was decreased at low pH (6.66) relative to neutral pH 
(7.45), suggesting that nitrite may have an important vasodilatory role in acidic conditions. 
This effect was inhibited by the co-administration of the soluble guanylyl cyclase inhibitor -[1, 
2, 4]-oxadiazolol-[4,3,-a]-quinoxalin-1-one (ODQ) suggesting that the vasorelaxatory effect of 
nitrite was dependent on its reduction to NO [41]. In further support of this requirement for 
reduction of nitrite, the reducing agent ascorbic acid potentiated nitrite’s vasorelaxatory 
effect. Overall, nitrite appeared to have vasodilatory effects on blood vessels via reduction to 
NO. 
Therefore, a hypoxic/acidic/ischaemic environment appeared to be necessary for nitrite 
reduction to bioactive NO. However, Cosby et al. (2003) found that forearm blood flow was 
increased by intra-brachial infusion of nitrite (36 and 0.36 µmol/min), resulting in supra- and 
near physiologic nitrite concentrations, respectively [42]. This vasodilatory effect was 
enhanced by handgrip exercise, which is associated with greater oxygen extraction from the 
circulation by the exercising forearm musculature, with a resultant greater formation of 
deoxyhaemoglobin (deoxyHb) possessing greater capacity for nitrite reduction, as evidenced 
by the formation of iron-nitrosylated haemoglobin (Hb). This requirement for hypoxia was 
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confirmed by Maher et al. who demonstrated that nitrite-induced vasodilatation with 
intrabrachial nitrite infusions (40 nmol/min to 7.84 μmol/min) was enhanced in hypoxic 
environments compared to normoxia in humans as assessed by forearm blood flow [43].   
 
4. How is nitrite reduced to NO?  
The description of enzyme-independent NO formation from nitrite by Zweier et al. referred to 
the lack of involvement of NOS [22]. Whether NO production was solely a result of the acidic 
disproportionation of nitrite, or other enzymes were involved in nitrite metabolism was not 
clear. However, identifying the mechanisms involved in controlling the reduction of nitrite to 
NO is crucial for understanding nitrite’s physiological effects. As described above, Cosby et 
al. showed that NO production from nitrite, considered to be responsible for the vasodilatory 
effect, was confirmed by the rate of formation of iron-nitrosylated Hb during artery to vein 
transit [42]. The rate of NO formation increased as oxygen saturations fell, suggesting a 
hypoxia-regulated mechanism of nitrite bioactivation [11]. Maximal reduction of nitrite to NO 
occurred at an Hb oxygen saturation of ~50% (around the p50 of Hb), representing the 
optimum balance point for maximal availability of Hb in the deoxy- T-state for nitrite to bind 
to, coupled with maximal availability of Hb in the oxy- R-state for reduction to NO [44, 45] 
[46, 47]. This mechanism of NO formation is therefore dependent on three factors, as 
highlighted by equation 1: circulating nitrite as a substrate, the presence of hypoxia (as 
determined by the level of deoxyHb) and the presence of an acidic environment as a source 
of H+. 
DeoxyHbFe(II) + NO2
- + H+   Hb + HNO2   Hb-NO + OH
-  HbFe(III) + NO + OH-  
(Equation 1) 
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The other ubiquitous globin, deoxymyoglobin (deoxyMb) reduces nitrite approximately 36-
times faster than deoxyHb, because of its lower redox potential, and is therefore likely to be 
a very important nitrite reductase. The rate of reduction by deoxyMb is increased in lower pH 
environments. Myoglobin-dependent NO generation occurs as a large burst; whereas Hb-
dependent NO generation is much more prolonged in comparison [48]. This may reflect 
different functions of nitrite reduction in these two molecules. Myoglobin (Mb) possesses a 
greater affinity for oxygen and hence nitrite reduction occurs more readily at very low oxygen 
tensions. Indeed, deoxyMb has been shown to be an effective nitrite reductase [46, 49], 
catalysing the production of NO ~36-fold faster than deoxyHb [49].  Therefore, the burst of 
nitrite reduction allows for better regulation of oxygen gradients under hypoxia, relating to the 
level of NO generation. In addition to Hb and Mb, deoxygenated neuroglobin (Ngb) and 
cytoglobin (Cgb) have been shown to reduce nitrite to NO [50, 51]; however, their low 
abundance questions their significance as nitrite reductases under physiological conditions 
[52, 53].   
 
Besides the haem-containing globins, several studies have highlighted the nitrite reductive 
capacity of the molybdo-flavoproteins, in particular xanthine oxidoreductase (XOR) [24, 54].  
Webb et al. showed that the production of NO from nitrite in rat and human heart 
homogenates was diminished in the presence of XOR inhibitors by ~50%, suggesting a role 
for XOR as a cardiac nitrite reductase [24]. Four years later, Webb et al. also showed XOR 
to be present on red blood cell membranes in addition to blood vessels (left internal 
mammary artery) offering readily-accessible sites for nitrite reduction within the circulation 
[55]. The activity of this XOR was upregulated with increasing acidosis and during hypoxia.  
[56, 57]. This provides a regulatory mechanism for nitrite’s increased activity in ischaemic 
tissue. In addition to XOR, the related molybdo-flavoprotein, aldehyde oxidase appears to 
function as a nitrite reductase [58]. Aldehyde oxidase is unable to function as a 
dehydrogenase [58, 59], and is not to be confused with the aldehyde dehydrogenases. 
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Although, aldehyde dehydrogenase 2 (ALDH2), which when deficient is associated with 
oriental (alcohol) flush, may also have nitrite reductase properties [60].   
The zinc-containing enzyme carbonic anhydrase (CA) has also been shown to catalyse the 
conversion of nitrite to NO [61]. However, since zinc in CA lacks redox activity, the enzyme 
is thought to function as a nitrous anhydrase, rather than a nitrite reductase, forming N2O3 
which then rapidly breaks down to form NO2 and NO, or forming nitrosothiols in the presence 
of thiols (e.g. glutathione), via zinc thiolate and nitrous acid (HNO2) [62]. Definitive 
production of CA-catalysed NO from nitrite has been difficult to demonstrated, with some 
studies showing no evidence for this [63]. Finally, whilst initially NOS was thought to lack 
capacity to function as a nitrite reductase, work by Gautier et al., identified such activity for 
eNOS, located within the oxygenase domain [64]. Subsequently, biological relevance was 
shown in human erythrocytes, whereby inhibition with L-NAME attenuated the production of 
NO from nitrite [55].   
5. Can nitrate generate nitrite-NO? 
The potential of dietary nitrate as a source of gastric NO was first demonstrated by two 
independent groups in 1994. However, these were viewed as local processes specifically 
related to the acidic environment of the stomach, with relevance strictly restricted to local 
biological processes (and not as a systemic source of NO).  Benjamin et al. demonstrated a 
10-fold increase in salivary nitrite concentration 45 min after ingestion of potassium nitrate 
(200 mg (2 mmol nitrate)) in fasting individuals [65]. The entero-salivary circulation of nitrate 
to nitrite had been described previously, whereby ingestion of nitrate-containing vegetable 
juices of varying concentration correlated with salivary nitrite concentrations, due to 
concentration of ~25% of the nitrate load in the salivary glands, with subsequent secretion 
and reduction to nitrite [66]. However, the possibility that such nitrate-derived nitrite might be 
a source of NO had not been. Whilst stomach NO was not measured by Benjamin et al. in 
this study, concentrations of nitrite such as those found in saliva, e.g. 250 μM, were found to 
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kill Candida albicans and Escherichia coli in a pH-dependent manner, an effect that was 
likely to have been due to the production of NO.   
Lundberg et al. did measure gastric NO production (in healthy and atopic individuals), with 
samples obtained through carbonated water-induced eructation and measured by ozone 
chemiluminescence [67]. Gastric NO production was found to be 100-times higher than 
exhaled NO. Ingestion of lettuce (50 g, ~1 mmol nitrate) just 5 minutes prior to measurement 
of gastric NO increased the concentration 5-fold. Moreover, gastric NO production was 
inhibited ~95% following ingestion of high dose proton pump inhibitor (PPI) omeprazole 
(three doses of 80 mg taken over the preceding 24 hour period) with or without lettuce 
ingestion. Therefore, nitrate was confirmed as a source of NO in the stomach, which was 
dependent on low pH (typical stomach pH 1-3, without PPI).  
Duncan C. et al. found that the salivary production of nitrite was due to bacteria on the 
posterior third of the tongue with nitrate reductase activity, which was absent in germ-free 
rats [68]. Following this, McKnight et al. found that ingestion of potassium nitrate (2 mmol) 
led to a sustained rise in salivary, gastric and plasma nitrate, salivary nitrite and gastric NO 
concentration for the duration of the study [69]. However, there was a small, non-significant 
rise in gastric nitrite, which suggested that the majority of the nitrite was rapidly converted to 
NO.  
Therefore, the understanding of the entero-salivary circulation was that nitrate is readily 
taken up in the upper gastrointestinal (GI) tract, plasma levels rise and remain elevated. 
Once in the circulation, ~25% of the nitrate load is actively absorbed and concentrated by 
the salivary glands. Following secretion of nitrate-containing saliva into the oral cavity, 
commensal, facultative anaerobic bacteria reduce nitrate to nitrite via nitrate reductases – an 
important step since mammalian cells cannot effectively metabolise this nitrate [70]. Nitrite is 
then swallowed in the saliva to enter the low pH stomach milieu, where it is rapidly 
protonated to form nitrous acid (HNO2) which then decomposes, via the reactions shown in  
Equations 2-5 to form NO [11].  
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 H+ + NO2
-    HNO2                (Equation 2) 
HNO2  NOOH                 (Equation 3) 
NOOH + NO2
-  N2O3 + OH
-               (Equation 4) 
N2O3 NO2 + NO                 (Equation 5) 
 
6. Does nitrate inhibit platelets?  
Platelet adhesion and aggregation are pivotal mechanisms in the pathogenesis of acute 
coronary syndrome and stroke [71]. McKnight et al. showed that an oral nitrate load in 
healthy volunteers resulted in significant inhibition of platelet activity when compared to the 
control (chloride solution) [72]. However, at that time, the mechanism by which nitrate 
resulted in platelet inhibition was not known. One possibility was the formation of S-
nitrosothiols (RSNOs), from the S-nitrosylation of thiol-containing compounds in the 
presence of by nitrosating species derived from nitrite in the acid milieu of the stomach: 
HNO2, N2O3 and NO
+. S-nitrosothiols were known to be potent inhibitors of platelet function 
in vitro and in vivo via cGMP-dependent and independent mechanisms [73].  
7. Does nitrate inhibit platelets via SNOs?  
Richardson et al., (2002) found that the ingestion of potassium nitrate (0.5 mmol and 2 
mmol) by healthy volunteers increased gastric RSNO concentration and inhibited the platelet 
response to collagen. However, there was no increase in plasma or portal blood RSNO, the 
latter measured in patients with transjugular intrahepatic portosystemic shunts (TIPS) [74]. 
Although there was an association between a rise in gastric RSNO and inhibition of platelet 
function, it was unclear whether S-nitrosothiols exerted a direct effect on platelet function. 
There was also no increase in platelet cGMP levels. Additional studies, using electron 
paramagnetic spectrometry as well as ozone chemiluminescence, obtained similar findings – 
an increase in gastric RSNO concentration following ingestion of nitrate, with no significant 
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change in plasma RSNO concentration [75]. As plasma nitrite was not thought to increase 
following a nitrate load, plasma nitrite was not measured in these studies. 
8. Does nitrate increase plasma nitrite? 
Whilst ingestion of nitrate led to a large rise in plasma nitrate concentration, it was unclear 
whether nitrite levels increased in a similar way. Pannala et al. analysed the pharmacokinetic 
profile of nitrate and nitrite in plasma, urine and saliva following a high nitrate meal (120 g of 
lettuce - equivalent to 250 mg of nitrate, once daily for three days). They found that whilst 
salivary nitrite increased significantly, there was no significant increase in plasma nitrite (78 
± 4 nmol/L and 90 ± 3 nmol/L pre- and post-meal, respectively). On the other hand, plasma 
nitrate rose almost 7-fold [76]. Therefore, the explanation for the effects of dietary nitrate on 
platelet aggregation was not at all clear. As Figure 1 shows, nitrite did not appear to be 
absorbed from the gut into the circulation, and it was unclear whether RSNOs were 
absorbed. Besides this there was major doubt anyway whether nitrite had physiologically-
relevant effects; even if it did, it seemed clear at the time that nitrate’s effect were not 
mediated by nitrite. 
 
In 2004, Lundberg and Govoni found that plasma nitrite concentration increased 4-fold in 
healthy participants following consumption of sodium nitrate (10 mg/kg), an effect that was 
prevented when volunteers avoided swallowing after the nitrate load [77]. The importance of 
lingual bacterial nitrate reduction was also shown in the same year in a study in germ-free 
sterile rats which showed that gastric NO production was negligible, even following a nitrate 
load [78].  Webb et al. also measured nitrite concentrations after ingestion of nitrate (500 mL 
beetroot juice) in healthy volunteers. They found that plasma nitrite concentrations increased 
significantly compared to control, peaking at ~3 hours after beetroot juice ingestion, returning 
to baseline levels by 24 hours [79]. A limitation in the study by Pannala et al. is that 
participant blood samples were measured only after 1 hour; whereas in the study by Webb 
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et al., a full kinetic profile of plasma nitrite levels was performed, which identified that a 
significant increase occurred around 2.5-3 hours post-ingestion. The delay in the peak of 
plasma nitrite, relative to plasma nitrate, is due to the time taken for nitrate to be absorbed 
through the enterosalivary circuit before reduction to nitrite, followed by accumulation in the 
circulation [80].  
 
9. Does Nitrate lower blood pressure? 
Given the finding of an increase in plasma nitrite following a nitrate load, coupled with the 
vasodilatory potential of nitrite as demonstrated by Cosby et al. [42], it was possible that 
dietary nitrate might lower blood pressure.  Larsen et al. conducted a randomised, cross-
over study in which healthy, non-smoking subjects were given sodium nitrate or sodium 
chloride (both 0.1 mmol/kg/day for 3 days). Whilst there was no change in systolic blood 
pressure, diastolic blood pressure was reduced by 3.7 mmHg by sodium nitrate, associated 
with almost a doubling in the  plasma nitrite concentration [80]. 
In the study by Webb et al, systolic blood pressure was significantly lower following 
consumption of 500 mL of beetroot juice containing ~22 mmol dietary nitrate (and 
undetectable amounts of nitrite) compared to control (500 mL of water) with a peak change 
at 2.5 hours of 10.4±3.0 mmHg (P<0.01). Peak decreases in diastolic and MAP were seen at 
3 hours after ingestion, with changes of 8.1±2.1 mmHg and 8.0±2.1 mmHg, respectively 
(both P<0.01) [79]. Since then, several studies have explored the effects of dietary nitrate on 
blood pressure, with 16 included in the meta-analysis of Siervo et al., (2013) which showed a 
mean difference in SBP of -4.4 mmHg (95% CI -5.9 to 2.8) [81].  
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10. Is nitrate’s BP lowering effect via nitrite? 
In the first study by Webb et al, the peak reduction in blood pressure occurred at 2.5-3 hours 
corresponding to the peak rise in plasma nitrite concentration, suggesting that nitrite, rather 
than nitrate, accounted for the change in blood pressure. To provide more evidence that 
blood pressure reduction with nitrate was related to plasma nitrite concentration, the 
enterosalivary circulation was interrupted by asking subjects to spit out all of their saliva for 3 
hours following beetroot juice consumption, or to swallow their saliva normally, in a further 
crossover study. Spitting saliva prevented the increase in plasma nitrite (plasma nitrate was 
unaffected) and prevented the decrease in systolic blood pressure seen with swallowing 
saliva normally. 
Kapil et al. established a dose-response relationship existed between nitrate consumption 
and change in plasma nitrate, nitrite and blood pressure using potassium nitrate capsules 
containing 4, 12 and 24 mmol [82]. Also, using potassium chloride capsules as control, it 
was confirmed that the blood pressure lowering effect was independent of potassium. 
Furthermore, the peak of plasma nitrite concentration was associated with significantly 
higher levels of circulating cGMP, a sensitive marker of NO bioactivity [83]. This study also 
gave some insight into individual differences in blood pressure lowering responses to nitrate. 
Baseline blood pressure was inversely correlated with the reduction in blood pressure, i.e. 
the higher the baseline, the larger the reduction in blood pressure. This suggested the 
possibility of better blood pressure-lowering responses in hypertensive individuals. A post-
hoc analysis also showed that females had a higher baseline concentration of nitrite than 
males, associated with the lack of a significant blood pressure reduction in response to 
nitrate. Therefore, baseline nitrite may predict the response of dietary nitrate-induced blood 
pressure reduction.  
It was now clear that the blood-pressure lowering effects of dietary nitrate were explained 
through the “nitrate-nitrite-NO pathway”, with nitrite being absorbed systemically. Therefore, 
nitrite held the key to the puzzle, as summarised in Figure 2.  
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Thus, nitrate is reduced to nitrite on the posterior surface of the tongue, which is then 
absorbed in the upper GI tract into the circulation. Nitrite then undergoes further reduction to 
produce the biologically active NO in the circulation. 
 
Conclusion 
We have described key twists and turns in the realisation of the nitrate-nitrite-NO pathway, 
highlighting some important physiological and therapeutic effects. These are summarised in 
Table 2. In Part 2 we explore more recently discovered properties and effects of nitrate and 
nitrite. 
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Table 1. The early ischaemia-reperfusion injury (IRI) studies with nitrite from 1995 until the 
first study in the dog heart (2008). Nonstandard abbreviations used: rate pressure product 
(RPP); left ventricular developed pressure (LVDP); heart rate (HR); alanine 
aminotransferase (ALT); aspartate aminotransferase (AST); haematoxylin and eosin (H&E); 
myeloperoxidase (MPO); serum creatinine (SCr); creatinine clearance (CCL); fractional 
excretion of Na (FENa+); left ventricular ejection fraction (LVEF). 
Study Organ/Route Measures of cytoprotection Outcome 
Zweier J. et al., 
1995 [22] 
Rat Heart IRI 
(Langendorff) 
Recovery of RPP, LVDP, HR Harmful 
Webb A et al., 
2004 [24] 
Rat Heart IRI 
(Langendorff) 
Infarct Size, Recovery of LVDP Beneficial 
Duranski et al.,  
2005 [27] 
Rat Liver (intra-
peritoneal) & Heart 
IRI 
(intraventricular) 
Liver – AST/ALT; H&E/TUNEL 
Heart – Infarct Size 
Beneficial 
Lu P et al., 
2005 [30] 
Rat Liver IRI ALT, MPO, ATP, 7d mortality, ATP Beneficial 
Jung et al., 
2006 [28] 
Rat Brain IRI Infarct Volume, Doppler flowmetry; 
neurological tests 
Beneficial 
Basireddy M et 
al., 2006 [31] 
Rat kidney IRI Serum creatinine and blood urea 
nitrogen  Histological scoring for loss of 
brush border, tubular necrosis, and red 
blood cell extravasation 
Neutral 
Tripatara P et 
al., 2007 [32] 
Rat Kidney IRI SCr, AST, CCL, Urine Flow, FE
NA
+, H&E Beneficial 
Bryan et al 
2007 [33] 
Mouse heart 7 days 
oral 
Infarct size Beneficial 
Shiva et al 
2007 [34] 
Mouse IRI Infarct size Beneficial 
Gonzalez et al., 
2008 [29] 
Dog Heart IRI Infarct Size, LVEF, MRI, Microsphere 
Blood Flow, TUNEL 
Beneficial 
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Table 2. Twists and turns in the realisation of the nitrate-nitrite-NO pathway 
 Negative/Neutral  Positive  
Background to nitrate’s (NO3
-) 
& nitrite’s (NO2
-) properties? 
Physiologically inert 
metabolites of NO [10] 
 
1. Is nitrite a source of NO?  No – nitrite is a 
physiologically inert 
metabolite of NO [10] 
Yes – in the ischaemic 
heart: Zweier et al.,1995 
[22] 
2. What effect does nitrite 
have in IRI? 
Deleterious - Zweier et al., 
1995 [22] 
Protective - Webb et al., 
2004  
3. Does nitrite dilate blood 
vessels?  
No – Lauer et al., 2001 [40] Yes - Modin et al., 2001 
[41], Cosby et al., 2003  
4. Are there nitrite 
reductases?  
Non-enzymatic/non-NOS  
Zweier et al.,1995 [22] 
Hb [42], Mb [85], XOR [24], 
AO [58], eNOS [64]  
5. Is nitrate a source of NO?   Benjamin et al., 1994 [65], 
Lundberg et al.,1994 [67] 
6. Does nitrate inhibit 
platelets? 
 Yes – McKnight et al., 1999 
[72] 
7. Does nitrate inhibit platelets 
via SNOs?  
No? – Richardson et al., 
2002 [74] 
 
8. Does nitrate increase 
plasma nitrite?  
No - Pannala et al., 2003 
[76] 
Yes – Lundberg et al., 2004 
[77], Webb et al., 2008 [79] 
9. Does nitrate lower BP?   Yes – Larsen et al., 2006 
[80], Webb et al., 2008 [79] 
10. Does nitrate lower BP via 
nitrite?   
 Yes – Webb et al., 2008 
[79] 
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Figure 1 – Compartmentalised kinetic model (involving the gut, circulation and urinary tract) 
of the kinetic processes understood to occur up to a decade ago in the handling of dietary 
nitrate (NO3
-), with the focus on S-nitrosothiol production from the nitrosating species (HNO2, 
N2O3, NO
+) generated in the stomach from acidic disproportionation (in addition to liberation 
of free NO gas), but uncertainty over systemic S-nitrosothiol absorption. The small amounts 
of residual nitrite (NO2
-) were not thought to be absorbed systemically. 
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Figure 2. Compartmentalised Model (involving the gut, circulation and urinary tract) of the 
fully realised ‘nitrate-nitrite-NO’ pathway.  Red and blue arrows represent pathways that are 
favoured under oxygenated and deoxygenated conditions, respectively [84]. 
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